These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28913538)

  • 1. Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study.
    Lee RFS; Riedel T; Escrig S; Maclachlan C; Knott GW; Davey CA; Johnsson K; Meibom A; Dyson PJ
    Metallomics; 2017 Oct; 9(10):1413-1420. PubMed ID: 28913538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
    Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Evaluation of Cisplatin Uptake in Sensitive and Resistant Individual Cells by Single-Cell ICP-MS (SC-ICP-MS).
    Corte Rodríguez M; Álvarez-Fernández García R; Blanco E; Bettmer J; Montes-Bayón M
    Anal Chem; 2017 Nov; 89(21):11491-11497. PubMed ID: 29023104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G; Li Y; Tian F
    Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Jaehde U
    J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
    Parekh H; Simpkins H
    Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
    Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
    Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment.
    Raaphorst GP; Chabot P; Doja S; Wilkins D; Stewart D; Ng CE
    Int J Hyperthermia; 1996; 12(2):211-22. PubMed ID: 8926390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
    Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
    Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
    Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
    Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical strategies to study the formation and drug delivery capabilities of ferritin-encapsulated cisplatin in sensitive and resistant cell models.
    Turiel-Fernández D; Blanco-González E; Corte-Rodríguez M; Bettmer J; Montes-Bayón M
    Anal Bioanal Chem; 2020 Sep; 412(24):6319-6327. PubMed ID: 32185440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical bioimaging for the subcellular localization of trace elements by high contrast TEM, TEM/X-EDS, and NanoSIMS.
    Penen F; Malherbe J; Isaure MP; Dobritzsch D; Bertalan I; Gontier E; Le Coustumer P; Schaumlöffel D
    J Trace Elem Med Biol; 2016 Sep; 37():62-68. PubMed ID: 27288221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
    Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
    Yellepeddi VK; Vangara KK; Kumar A; Palakurthi S
    Anticancer Res; 2012 Sep; 32(9):3651-8. PubMed ID: 22993302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative differences in protein expression between cisplatin sensitive C0C1 ovarian carcinoma cells and cisplatin resistant C0C1/DDP cells.
    Wang HX; Sun W; Li HL; Zhang WY
    Chin Med J (Engl); 2009 Apr; 122(7):865-9. PubMed ID: 19493403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.